Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock and Warrants
-
Shares outstanding
-
27.5M
-
Number of holders
-
35
-
Total 13F shares, excl. options
-
9.76M
-
Shares change
-
+255K
-
Total reported value, excl. options
-
$93M
-
Value change
-
-$3.68M
-
Number of buys
-
26
-
Number of sells
-
-8
-
Price
-
$9.53
Significant Holders of AN2 Therapeutics, Inc. - Common Stock and Warrants (ANTX) as of Q4 2022
40 filings reported holding ANTX - AN2 Therapeutics, Inc. - Common Stock and Warrants as of Q4 2022.
AN2 Therapeutics, Inc. - Common Stock and Warrants (ANTX) has 35 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9.76M shares
of 27.5M outstanding shares and own 35.54% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (3.77M shares), BVF INC/IL (1.56M shares), CITADEL ADVISORS LLC (1.34M shares), Avidity Partners Management LP (744K shares), VANGUARD GROUP INC (589K shares), Monashee Investment Management LLC (450K shares), BlackRock Inc. (445K shares), CITIGROUP INC (135K shares), GEODE CAPITAL MANAGEMENT, LLC (123K shares), and Woodline Partners LP (107K shares).
This table shows the top 35 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.